Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Deciphera Pharmaceuticals (DCPH)
NASDAQ:DCPH
RESEARCH TOOLSreports
Holding DCPH?
Track your performance easily
DCPH Stock Chart & Stats
Day’s Range$25.56 - $25.61
52-Week Range― - ―
Previous Close$25.57
Volume1.60M
Average Volume (3M)N/A
Market Cap
$2.21B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$24.40Price Target Upside-4.65% Downside
Rating ConsensusHold
Number of Analyst Covering8
Deciphera Pharmaceuticals News
PremiumCompany Announcements
Deciphera Pharmaceuticals: Significant Post-Merger Corporate Changes
Bulls Say, Bears Say
Bulls Say
Acquisition PremiumThe acquisition by Japanese Pharma Company Ono Pharmaceutical Co., Ltd in an all-cash transaction represents a total equity value of $2.4bn and a 74.7% premium over the previous closing price, offering substantial value to Deciphera shareholders.
Drug Development ProgressDeciphera's vimseltinib, showing promising results in the MOTION trial for treating tenosynovial giant cell tumor, is positioned for regulatory submissions, potentially leading to new treatment options and increased company value.
Strategic Acquisition BenefitsThe unanimous approval by both companies' boards and the alignment with Ono Pharmaceutical's oncology focus suggest a strategic fit that could enhance market presence in the US and EU, benefiting stakeholders.
Bears Say
Clinical DevelopmentsEmerging safety signals for vimseltinib could impact the valuation.
Corporate StrategyPotential failure of the Ono Pharma deal to close poses a risk.
Earnings PerformanceQinlock product sales at $42.55 mn was below consensus of ~$45.3 mn by ~6% and below previous quarter sales.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DCPH FAQ
What was Deciphera Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Deciphera Pharmaceuticals’s market cap?
Currently, no data Available
When is Deciphera Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Deciphera Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Deciphera Pharmaceuticals overvalued?
According to Wall Street analysts Deciphera Pharmaceuticals’s price is currently Overvalued.
Does Deciphera Pharmaceuticals pay dividends?
Deciphera Pharmaceuticals does not currently pay dividends.
What is Deciphera Pharmaceuticals’s EPS estimate?
Deciphera Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Deciphera Pharmaceuticals have?
Currently, no data Available
What happened to Deciphera Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Deciphera Pharmaceuticals?
Among the largest hedge funds holding Deciphera Pharmaceuticals’s share is Deerfield Management Company, LP. It holds Deciphera Pharmaceuticals’s shares valued at 81M.
---
Deciphera Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$24.40 (-4.65% Downside)
$24.40 (-4.65% Downside)
Blogger Sentiment
Bullish
DCPH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $481.4 over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-50.37%
Trailing 12-Months
Asset Growth
-23.33%
Trailing 12-Months
Company Description
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
---
DCPH Stock 12 Month Forecast
Average Price Target
$24.40
▼(-4.65% Downside)
Technical Analysis
Best Analysts Covering DCPH
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
+27.39%
reiterated a buy rating 10 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +27.39% per trade.
---